ClinicalTrials.gg
RecruitingNCT05789940HARETUpdated Jun 22, 2026

Hysteroscopy vs. Endouterine Aspiration in the Management of Trophoblastic Retention

An interventional study of hysteroscopy and Aspiration in Miscarriage, sponsored by University Hospital, Montpellier. Recruiting at 4 sites in France. Open to female participants aged 18 Years to 42 Years. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
18 Years to 42 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Abortion, Spontaneous with a site in France — 7 open to participants now, 8 under way, none of them phase 3. Abortion, Spontaneous · France.

Planned enrollment
7th of 14
220 · median 210
Started
2023
with 1 other
No phase
12 of 27
5 open now
Registered
21st of 27
by date
Lead sponsor
4 of 27
University Hospital, Montpellier

Among the 27 studies in Abortion, Spontaneous with a site in France, this one is the 7th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2023, is one of 12 with no phase, and was the 21st registered.

Abortion, Spontaneous

221 studies on the registry are indexed under Abortion, Spontaneous; 44 are open to participants now.

Browse Abortion, Spontaneous studies →

Open to participants now

7 of the 27 studies in Abortion, Spontaneous with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 36 Abortion, Spontaneous studies recruiting now, 11 (31%) set no upper age limit and 25 (69%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 42 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Abortion, Spontaneous with a site in France, or all of them as a file.
02

Study summary

Introduction: Incomplete early miscarriage is defined as early miscarriage with persistent intrauterine material on ultrasound. Intrauterine retention of trophoblastic debris is not an uncommon phenomenon. These retentions may initially be asymptomatic but are often responsible for persistent metrorrhagia and endometritis. This symptomatology often accentuates the psychological distress of patients mourning the pregnancy. Incomplete miscarriages are mainly managed by the gynecological emergency department. The recommendations of the Collège National des Gynécologues et Obstétriciens Français (CNGOF) suggest as a first line of treatment: either surgical management or expectant care. The choice between the two is left to the discretion of the doctor and the patient. there are no clear recommendations as to the choice between hysteroscopy and aspiration. Within the teams, the choice is often made according to the habits and protocols of the service, according to the equipment available and the skills of the gynaecologists.

Aim: The main objective is to compare the efficacy of management by endo-uterine aspiration vs. management by hysteroscopy of trophoblastic retention after early miscarriage, at 6 weeks after surgery, by endovaginal ultrasound.

Methods: This is a prospective, multicenter, randomized, open-label, two-arms, parallel therapeutic clinical trial comparing hysteroscopy versus endouterine aspiration for the management of trophoblastic retention after spontaneous miscarriage.

Patients will be randomized (110 per arm) after verification of eligibility criteria and signature of consent, on the day of the operation:

  • Arm A: 110 patients treated by operative hysteroscopy
  • Arm B: 110 patients treated by endo-uterine aspiration
Read the detailed description

Introduction: Incomplete early miscarriage is defined as early miscarriage with persistent intrauterine material on ultrasound. Intrauterine retention of trophoblastic debris is not an uncommon phenomenon. These retentions may initially be asymptomatic but are often responsible for persistent metrorrhagia and endometritis. This symptomatology often accentuates the psychological distress of patients mourning the pregnancy. Incomplete miscarriages are mainly managed by the gynecological emergency department. The recommendations of the Collège National des Gynécologues et Obstétriciens Français (CNGOF) suggest as a first line of treatment: either surgical management or expectant care. The choice between the two is left to the discretion of the doctor and the patient. there are no clear recommendations as to the choice between hysteroscopy and aspiration. Within the teams, the choice is often made according to the habits and protocols of the service, according to the equipment available and the skills of the gynaecologists.

Aim: The main objective is to compare the efficacy of management by endo-uterine aspiration versus management by hysteroscopy of trophoblastic retention after early miscarriage, at 6 weeks after surgery, by endovaginal ultrasound.

The secondary objectives are:

  • the comparison of the rate of complications of the two techniques, during and after surgery
  • the comparison of the rate of recourse to a second line surgical management between the two arms,
  • the comparison of the rate of synechiae diagnosed by hysterosonography between the two techniques at 6 weeks after surgery,
  • the comparison of the time to conception in the two arms during the 2 years after surgery
  • the comparison of the fertility rate at 2 years after surgery in the two arms.

Methods: This is a prospective, multicenter, randomized, open-label, two-arms, parallel therapeutic clinical trial comparing hysteroscopy versus endouterine aspiration for the management of trophoblastic retention after spontaneous miscarriage.

Patients will be randomized (110 per arm) after verification of eligibility criteria and signature of consent, on the day of the operation:

  • Arm A: 110 patients treated by operative hysteroscopy
  • Arm B: 110 patients treated by endo-uterine aspiration Randomization will be stratified by center, age (\<35 years, 35 years and over), size of trophoblastic retention (\<30mm, 30mm and over) and scheduled by random size block. It will be centralized (Ennov-clinical software) and parameterized by the Unité́ de Recherche Clinique \& Biostatistiques of the Montpellier University Hospital.

Statistics: The effectiveness of operative hysteroscopy is expected to be 100%, and that of aspiration 90%. To show this difference with an alpha risk of 5%, and with a power of 90%, 98 patients per arm will have to be analysed (exact binomial distribution calculation, epiR package of R implemented in biostatgv). To take into account a 10% loss of sight rate, 220 patients will be recruted.

Patients will be included in the study on the morning of the procedure, after verification of the selection criteria.

The expected number of lost to follow-up is estimated at 10%; in fact, the main criterion is evaluated relatively early (6 weeks), in patients having a desire for pregnancy and therefore relatively compliant, the rate of lost to follow-up will be a fairly low.

A flow-chart will be constructed to describe the evolution of the populations during the study. It will detail the causes of non-inclusion and the causes of loss to follow-up.

All study data will be described according to the randomization arm, in the randomized population: mean, standard deviation, median and quartiles, extrema and number of missing data for quantitative variables, numbers and percentages of each modality for qualitative data.

The clinical comparability of the randomized population and the ITT population for the primary endpoint will be assessed.

Primary analysis:

The uterine vacuity rate will be compared between the two arms in the ITT population for the primary endpoint by a Chi-square test or by a Fisher exact test if the conditions for Chi-square validity are not met. The significance level was set at 5%, two-sided.

Secondary endpoint analysis:

The rates of complications, use of second-line surgical management, synechiae, and fertility at 2 years after surgery will be compared between the two arms in their respective ITT populations, by a Chi-square test or by a Fisher's exact test if the conditions for the validity of Chi-square are not met.

The time to conception will be compared between the two arms of the randomized population by a log-rank test.

Within this family of endpoints, the alpha risk will be controlled by a Hochberg procedure.

Visit 1: Pre-operative consultation between 1 and 21 days before the operation

  • Clinical examination performed as part of routine care: measurement of blood pressure and pulse, temperature, speculum examination to ensure the absence of significant bleeding indicating emergency surgical management.
  • Diagnosis of trophoblastic retention by endovaginal ultrasound

At the end of the consultation:

  • Verification of eligibility criteria
  • Oral information on the study and information leaflet given to the patient
  • Collection of informed and written consent after a reflection period
  • Collection of the following data:
  • Demographic data
  • History, smoking habits and concomitant treatments
  • Pregnancy data leading to the current miscarriage
  • Results of pelvic ultrasound

Intervention (D0):

  • Verification of eligibility criteria and randomization on the morning of the procedure
  • Surgical management of trophoblastic retention by operative hysteroscopy (Arm A) or endo-uterine aspiration (Arm B)
  • Collection of adverse events during the operation and before the patient is discharged

Visit 2: Consultation at 6 weeks after surgery +/- 7 days

This consultation will be performed by an investigator trained in pelvic ultrasound and hysterosonography, blinded to the allocated procedure:

  • Plasma HCG measurement before hysterosonography to ensure that there is no current pregnancy
  • Endovaginal ultrasound to check uterine vacuity
  • Hysterosonography for the diagnosis of uterine synechia
  • Collection of complications and adverse events after surgery

Visit 3: Telephone consultation at 6 months +/- 15 days after surgery

Carried out by the clinical research associate (CRA):

  • Evaluation of fertility by questionnaire
  • Evaluation of the time to conception if pregnancy in progress A letter will be sent to the patient if she cannot be reached by phone (questionnaire + return envelope)

Visit 4: Telephone consultation at 12 months +/- 1 month after surgery

Carried out by the CRA:

  • Evaluation of fertility by questionnaire.
  • Evaluation of the time to conception if pregnancy in progress. A letter will be sent to the patient if she cannot be reached by phone (questionnaire + return envelope)

Visit 5: Telephone consultation at 24 months (+/- 2 months) after surgery

Carried out by the CRA:

  • Evaluation of fertility by questionnaire
  • Evaluation of the time to conception if pregnancy in progress A letter will be sent to the patient if she cannot be reached by phone (questionnaire + return envelope). The patients will be followed until a pregnancy is obtained with a term greater than or equal to 24 weeks of amenorrhea or over a maximum period of 26 months after the surgery.
03

Conditions studied

  • Miscarriage

Browse trials for

Keywords

  • Miscarriage
  • Hysteroscopy
  • Aspiration
  • Fertility
  • Synechiae
04

Who can participate

Ages eligible
18 Years to 42 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Management for trophoblastic retention after early spontaneous miscarriage (\<14 weeks of amenorrhea)
  • Diagnosis of intrauterine trophoblastic retention by endovaginal pelvic ultrasound
  • Shared decision for surgical management

Exclusion criteria

Exclusion Criteria:

  • Known uterine malformation
  • Patient who has received surgical treatment for current intrauterine retention
  • Patient with an intrauterine device (IUD)
  • Pregnancy obtained by medically assisted procreation
  • Indication for emergency surgical management for haemostatic purposes
  • Failure to obtain free, informed and written consent after a period of reflection
  • Person not affiliated or beneficiary of a national health insurance system
  • Person protected by law, under guardianship or curatorship
  • Person participating in other interventional research involving the human person
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Arm A: Hysteroscopy

    Patients randomized to the hysteroscopy arm will receive misoprostol antibiotic prophylaxis to dilate the cervix before surgery, and anti-adhesion barrier gels will be used, according to routine procedures at each center. In case of intrauterine retention complicated by endometritis, antibiotic treatment for 48 hours (penicillin, metronidazole, fluoroquinolones or a combination of these antibiotics) will be administered according to the standard practice of each center. Evacuated retention product will be sent for pathological examination. Rh-negative women will receive prophylaxis to prevent Rh alloimmunization.

    Procedure: hysteroscopy

  • Experimental
    Arm B: Aspiration

    Patients randomized to the aspiration arm will receive misoprostol antibiotic prophylaxis to dilate the cervix before surgery and anti-adhesion barrier gels will be used, according to routine procedures at each center. In case of intrauterine retention complicated by endometritis, antibiotic treatment for 48 hours (penicillin, metronidazole, fluoroquinolones or a combination of these antibiotics) will be administered according to the standard practice of each center. Evacuated retention product will be sent for pathological examination. Rh-negative women will receive prophylaxis to prevent Rh alloimmunization.

    Procedure: Aspiration

Interventions

  • Procedurehysteroscopy

    The procedure is performed by a gynecologic surgeon under general or spinal anesthesia, depending on the standard practice of the center involved, with the patient in the gynecologic position. Antibiotic prophylaxis may be administered according to the standard practice of the center. The equipment available at each center will be used for operative hysteroscopy. The use of energy is usually unnecessary and saline will be preferred. Before the operation, the appearance of the uterine cavity will be described. The selected design product will be resected from top to bottom using the surgical resector, without electrical energy, as this method is known to be the most protective of the endometrium in previous studies. Electric current should be used only as a last resort, in cases where the selected design cannot be removed without it. If there is active bleeding after the procedure, elective coagulation via the hysteroscope may be performed to stop intrauterine bleeding.

  • ProcedureAspiration

    The aspiration will be performed by a gynecological surgeon, according to the center's standard protocol. A flexible or rigid cannula can be used. Antibiotic prophylaxis, the diameter of the cannula used, the cervical preparation required, and the use of intraoperative ultrasound guidance will be left to the discretion of the operator and the standard practice of the center. In most centers, the cervix is dilated with a Hegar dilator of up to 9 mm in size.

06

What researchers measure

Primary outcomes

  1. Uterine vacuity

    Uterine vacuity will be determined by endovaginal pelvic ultrasound. The endovaginal pelvic ultrasound will be performed by an investigator blinded to the patient's group, in order to minimize bias. It will be performed according to a standard pelvic ultrasound technique: a sagittal section and a transverse section passing through the widest part of the uterine body. Uterine vacuity will be defined by a thickness of the mucosa on a sagittal section of 15 mm or less and the absence of a heterogeneous intrauterine mass

    Time frame: 6 weeks after surgery

Secondary outcomes

  1. Difference between the two arms in complication rates

    Complications will be described according to clavien-dindo classification

    Time frame: During surgery and 6 weeks after surgery

  2. Difference between the two arms in the rate of second line surgical management

    The rate of second line surgical management will be described

    Time frame: During surgery

  3. Difference between the two arms in synechia rates

    Presence of synechia will be assessed by hysterosonography

    Time frame: 6 weeks after surgery

  4. Difference between the two arms in mean time to conception

    Patients will be contacted by phone at 6, 12 and 24 months after the surgery to ask if they have been pregnant et evaluate the time of conception

    Time frame: 6, 12 and 24 months after surgery

  5. Difference between the two arms in pregnancy rates

    Patients will be contacted by phone at 6, 12 and 24 months after the surgery to assess their fertility

    Time frame: 6, 12 and 24 months after surgery

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Sep 2027, 48 months after the start.

Of 43 non-industry interventional studies with no phase under Abortion, Spontaneous, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 48 months is above that.

Counting every sponsor, half of 45 studies reached it within 27 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2023
First posted
Mar 29, 2023
StartActual
Sep 18, 2023
Primary completionEst.
Sep 18, 2027
CompletionEst.
Sep 18, 2029
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05789940
Responsible party
Sponsor
First posted
Mar 29, 2023
Start date
Sep 18, 2023
Primary completion
Sep 18, 2027 (estimated)
Completion
Sep 18, 2029 (estimated)
Last update
Jun 22, 2026

Study contacts

Martha DURAES, MD
Contact
m-duraes@chu-montpellier.fr
+334 67 33 65 32
Elodie GUIBERT, CRA
Contact
elodie.guibert@chu-montpellier.fr
+334 67 33 53 17
Martha DURAES, MD
study director · CHU de Montpellier

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion